Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Stem Cell Transplantation for Sickle Cell Disease Using Lenti/G-βAS3-FB
NCT02247843Phase 2Completed
- Start
- Dec 2014
- Primary completion
- Sep 2025
- Modality
- Gene Editing, Adoptive Cell Transfer, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of βAS3-FB vector transduced peripheral blood CD34+ cells in sickle cell disease (SCD). Primary endpoint: Evaluation of Safety at 24 months. Started Dec 2014; status: completed.
02
Drugs
βAS3-FB vector transduced peripheral blood CD34+ cells
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02247843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02247843.